保持在范围内的重要性:塔克罗利斯患者内变异性与脏移植结果之间的关联
Louise Benning1, Lisa Wittig1, Marvin Reineke1
1Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany.
Frontiers in immunology
|February 16, 2026
概括
维持最佳的塔克罗利斯水平对于移植成功至关重要. 暴露不足显著增加了移植失败,排斥和患者死亡的风险,突出了精确免疫抑制管理的必要性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 移植免疫学 移植免疫学
- 药理动力学 药理动力学
背景情况:
- 移植是末期病的首选治疗方法.
- 保持在治疗范围内的免疫抑制对于移植的生存至关重要.
- 塔克罗利斯是一种关键的免疫抑制剂,需要仔细监测.
研究的目的:
- 评估不同的塔克罗利斯暴露指标的临床相关性.
- 评估塔克罗利斯暴露与移植后结果之间的关联.
- 在移植接受者中确定最佳的塔克罗利斯监测策略.
主要方法:
- 对372名成年已故捐赠者移植的回顾性分析.
- 在移植后90-180天内计算塔克罗利斯暴露指标 (IPV,分数,最低低谷,AUC).
- 分析了5年移植存活率,患者存活率和3年无排斥存活率.
主要成果:
- 高达克罗利斯患者内变异性 (IPV) 和高分数增加了排斥风险.
- 低于目标水平 (AUC) 的时间和最低低谷水平 (<5 ng/mL) 与移植失败,患者死亡和排斥有很强的联系.
- 在塔克罗利斯暴露指标和供体特异性抗体 (DSA) 发育之间没有发现任何关联.
结论:
- 多种塔克罗利斯暴露不足的标志物独立地预测了移植后的不良结果.
- 在目标治疗范围内保持塔克罗利斯水平至关重要.
- 优化早期移植后免疫抑制管理可以改善长期移植结果.
相关概念视频
Kidney Transplant I: Introduction
514
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
514
Kidney Transplant III: Nursing Management
417
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
417
Kidney Transplant II: Surgical Procedure
462
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
462
Acute Kidney Injury IV: Diagnostic Studies and Prevention
354
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
354
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
235
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
235
Renal Drug Excretion: Tubular Secretion
952
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
952


